Pharmaceutical Research and Manufacturers of America (PhRMA) asked a federal district court yesterday to rule that Arkansas’s 340B nondiscrimination act does not require drug manufacturers “to offer price discounts under the 340B program to contract pharmacies in Arkansas.”
…
A recent U.S. Supreme Court ruling about administrative law judges who hear patent disputes confirms that rules establishing the 340B program’s administrative dispute resolution (ADR) process are constitutional, government lawyers told a federal district judge this month.
A federal district judge this week gave six hospital groups and a drug industry services provider permission to separately offer their expert advice in drug manufacturer Sanofi’s 340B contract pharmacy lawsuit.
It appears increasingly likely that congressional Democrats will miss their self-appointed deadline to pass and sent to President Biden this week a $3.5 trillion economic and social welfare bill including major drug pricing reforms.
A Republican U.S. senator on an important health care spending committee wants Congress to pass a law preserving the Trump administration’s controversial requirement that community health centers pass along all their 340B savings on insulin and EpiPen-like devices to low-income,
…
Six national hospital groups late last week urged Democratic and Republican congressional leaders to exclude language “that would negatively impact 340B” from major drug pricing reforms that could be voted on this week.
Drug manufacturer Janssen, a Johnson & Johnson company, has notified 340B covered entities they are or might be owed refunds for overcharges on 14 widely used products during the first and second quarters of 2021.
U.S. Sen. Chuck Grassley (R-Iowa)—one of the most-engaged members of Congress on 340B matters—has announced he will seek an eighth Senate term in next year’s congressional elections.
A federal judge yesterday denied drug maker Novartis’ request to speed up a hearing on its request that the judge block the government from punishing the company over its denials of 340B pricing when health care providers use contract pharmacies.
…
U.S. Sen. Mike Braun (R-Ind.) introduced legislation last night to let the federal government audit 340B covered entities to determine how they use net income from drugs bought under the 340B program.
